

#69

COMPLETE

Collector: Email Invitation 1 (Email)
Started: Tuesday, March 13, 2018 11:54:56 AM
Last Modified: Wednesday, April 25, 2018 11:05:46 AM
Time Spent: Over a month
First Name: [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Page 3: General Information

Q1 Focal point contact details

Name [REDACTED]
[REDACTED] onal
[REDACTED]; [REDACTED]
[REDACTED]
[REDACTED] e

Q2 Please indicate your country **Germany**

Page 4: WHO Data Sharing Policy

Q3 Please confirm that you agree **I agree for the information provided in this questionnaire to be published in a report**

Page 5: General cannabis information

Q4 Do you have any information about the use of CBD for any purpose (including medical or non-medical use) in your country? **Yes**

Page 6: Medical use

Q5 At national level, is CBD legally approved for medical use in your country? **Yes**

Page 7: Medical use: Therapeutic indications

WHO ECDD Questionnaire: Cannabidiol (CBD)

Q6 Please indicate any approved therapeutic indications for the use of CBD in your country

Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury

,

Other (please specify):

Concerning pharmacy-prepared medicinal products containing CBD there are no limitations to specific therapeutic indications.

Q7 Please indicate any symptoms that CBD is approved to treat

Other (please specify):

Concerning pharmacy-prepared medicinal products containing CBD there are no limitations to specific symptoms.

Q8 Please indicate whether there are any permitted marketed products of CBD.

Name of marketed product & CBD /THC content (if known):

Sativex (CBD/THC = 1:1)

Name of marketed product & CBD /THC content (if known):

Tilray THC10/CBD10 (permitted but not approved)

Q9 Are there any ongoing approved clinical trials in your country that are developing CBD for medical use?

Yes

Q10 Please indicate product name/ trial number/ study phase of any ongoing trials that are developing products of CBD for medical use

Product name

Cannabidiol / Dronabinol; Eudra-CT: 2012-004427-20; Phase:1

Product name

Cannabidiol; Eudra-CT: 2014-003215-11; Phase: 2

Product name

Cannabidiol; Eudra-CT: 2015-002154-12; Phase: 3

Product name

Cannabidiol; Eudra-CT: 2015-000465-31; Phase: 2

Product name

Cannabidiol; Eudra-CT: 2014-003215-11; Phase: 2

Product name

Cannabidiol; Eudra-CT: 2015-005244-34; Phase: 1

Page 8: Medical use: Access

Q11 Do individuals require a prescription to obtain medical CBD?

Yes

Q12 What types of professionals are allowed to prescribe CBD?

Medical doctor / psychiatrist

WHO ECDD Questionnaire: Cannabidiol (CBD)

Q13 What kinds of settings are approved to legally dispense CBD in your country?

Pharmacies

Q14 If patients use medical CBD on prescription or recommendation of a health professional, will they be reimbursed for the costs of their medication?

Other (please specify):
Authorised finished medicinal products containing Cannabis extracts with CBD are reimbursed for the approved indications. Pharmacy-prepared medicinal products containing Cannabis extracts with CBD are reimbursed for patients who are severely ill and who have no other alternative in therapies.

Q15 Are any clinical guidelines used in your country for the prescribing of medical CBD?

Yes (please specify):
The German Medical Association (Bundesärztekammer) has published a compilation of frequently asked questions relating to the medical prescription of Cannabis.

Q16 Is there a regulatory agency in your country that monitors CBD for medical use?

Yes (please specify):
Medicinal products containing CBD are subject to the pharmacovigilance system.

Q17 How would you describe the trend in the number of users of CBD for medical use over the last 3 years?

CBD

The number has slightly increased

Page 9: Medical use: National legislation

Q18 In the past 3 years, has your country changed its national legislation around access to cannabis-related substances for medical use?

CBD

Yes, my country has changed its legislation

Q19 If yes, what types of legislative changes has your country made for medical use of CBD?

Other (please specify):
In 2016 CBD was submitted to the ordinance on prescription requirements for medicinal products.

Q20 Is your country currently considering changes to its national legislation around access to cannabis and cannabis-related substances for medical use?

CBD

No, my country is not preparing changes in its legislation

WHO ECDD Questionnaire: Cannabidiol (CBD)

Q21 In your opinion, how do you feel the changed legislation around access to CBD for medical use would impact / has impacted public health in your country?

Increased availability for medical use

There would be/ has been a slightly positive impact on public health

Decreased availability for medical use

There would be /has been a slightly negative impact on public health

Page 10: Non-medical Use

Q22 On a national level, is CBD legally available for non-medical use in your country?

Other (please specify):
CBD - if classified as food - is a so-called novel food. For novel foods a pre-market authorisation on the basis of a risk evaluation is necessary in the EU according to Regulation (EU) 2015/2283. No approval has been granted yet for CBD under Regulation (EU) 2015/2283. Some cosmetic products containing CBD are offered on the market.

Q23 Is CBD used for cultural, ceremonial, or religious purposes in your country?

No

Q24 Does your country collect prevalence data around the use of CBD?

No

Page 11: Prevalence of non-medical cannabis use

Q25 Prevalence of use of CBD amongst adults (over 18 years of age)

Respondent skipped this question

Q26 Prevalence of use of CBD for non-medical use amongst young people (below 18 years of age)

Respondent skipped this question

Q27 How would you describe the number of users CBD for non-medical use over the last 3 years in your country?

Respondent skipped this question

Page 12: Public health impact of use: Primary Care

Q28 Does your country collect data about presentations to primary care settings due to the use of CBD?

No

Page 13: Primary Care II

WHO ECDD Questionnaire: Cannabidiol (CBD)

Q29 Number of primary care presentations relating to CBD **Respondent skipped this question**

Q30 Does your country collect data about presentations to emergency care settings due to the use of CBD? **No**

Page 14: Public health: Emergency settings

Q31 Number of individuals in the past year presenting to emergency settings relating to the use of CBD **Respondent skipped this question**

Q32 Please list the adverse effects presented for CBD at the emergency room/department **Respondent skipped this question**

Q33 Does your country collect data about presentations to substance misuse treatment settings due to the use of CBD? **No**

Page 15: Public health: Substance misuse treatment

Q34 Number of individuals in the past year presenting to substance misuse treatment due to CBD **Respondent skipped this question**

Q35 Does your country collect data about calls to poison centres due to the use of CBD? **No**

Page 16: Public health impact: Poison control centres

Q36 Number of calls to poison control centres due to the use of CBD **Respondent skipped this question**

Q37 Does your country collect data about cases of impaired driving due to the use of CBD? **No**

Page 17: Public health impact: Impaired driving

Q38 Number of cases of impaired driving due to CBD **Respondent skipped this question**

Page 18: Non-Medical Use: National legislation

WHO ECDD Questionnaire: Cannabidiol (CBD)

Q39 In the past 3 years, has your country changed its national legislation around access to CBD for non-medical use?

CBD **No, my country has not changed its legislation**

Q40 If yes, what types of legislative changes has your country made for non-medical use of CBD? **Respondent skipped this question**

Q41 Is your country currently considering changes to its national legislation around access to CBD for non-medical use?

Cannabis plant and cannabis resin **No, my country is not preparing changes in its legislation**

Q42 In your opinion, how do you feel the changed legislation around access to CBD for non-medical use would impact / has already impacted public health in your country?

Increased availability for non-medical use **Don't know/ unsure**

Decreased availability for non-medical use **Don't know/ unsure**

Page 19: Additional comments / information

Q43 Comments **Respondent skipped this question**

Q44 File upload

FAQ Cannabis_Bundesärztekammer.pdf (269.5KB)

Q45 File upload **Respondent skipped this question**

Q46 File upload **Respondent skipped this question**
